These agents target distinct molecular markers, such as gastrin-releasing peptide receptor (GRPR), translocator protein (TSPO), and integrin-αvβ3, that have been shown to be overexpressed in various CNS tumors [128,129,130,131,132]. Here, GRPR is linked to central nervous system neoplasm.